Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOMAS: Trabectedin and Olaparib in Advanced Sarcomas
NCT02398058Phase 1Completed
- Sponsor
- Italian Sarcoma Group
- Start
- Jul 2014
- Primary completion
- Dec 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trabectedin and olaparib in soft tissue sarcoma (STS) and Bone tumor (BT), sponsored by Italian Sarcoma Group. Primary endpoint: Maximum Tolerated Dose at 6 weeks. Started Jul 2014; status: completed.
02
Drugs
trabectedinolaparib
03
Conditions
soft tissue sarcoma (STS)Bone tumor (BT)
Beyond the preview
Go deeper on NCT02398058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02398058.